01402nam a2200241   4500001000800000005001700008007000300025008004100028040000800069041000800077100002900085245005500114300002500169520071000194650001300904650004200917650002400959650001800983650001601001650002301017700001701040773010301057ESSALUD20260903093950.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aDer, Channing J. eAutor  aAdvances in RAS therapeutics for pancreatic cancer  apáginas: 1857-1861  aSomatic mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) occur in more than 90% of pancreatic ductal adenocarcinomas. In this issue of the Journal, Wolpin et al. evaluated the side-effect profile of and response to a first-in-class small-molecule drug called daraxonrasib, which targets the active state of RAS (see Key Concepts) in patients with metastatic pancreatic ductal adenocarcinoma who have received at least one previous line of chemotherapy. In the context of second-line treatment, they reported an objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, in up to 35% of patients and a median response duration of 8.2 months.  aCÁNCER  aCÁNCER DEL TRACTO GASTROINTESTINAL   aGASTROENTEROLOGÍA  aHEMATOLOGÍA  aONCOLOGÍA  aGENÉTICA GENERAL  aYeh, Jen Jen0 022717dMassachusetts NEJM GroupoNEJM015tThe New England Journal of Medicine wESSALUDx0028-4793